New Haven, Conn. — November 24, 2025 — Leads & Copy — Arvinas, Inc., a clinical-stage biotechnology company (Nasdaq: ARVN), has announced the acceptance of multiple abstracts on vepdegestrant (ARV-471) for presentation at the San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9–12, 2025, in San Antonio, Texas.
Vepdegestrant, developed in collaboration with Pfizer Inc. (NYSE: PFE), is an investigational PROTAC estrogen receptor (ER) degrader. It is under evaluation as a potential monotherapy for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer, specifically with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. Studies are also assessing vepdegestrant both as a standalone treatment and in combination therapies for ER+/HER2- breast cancer.
The presentations will cover various aspects of vepdegestrant, including subgroup analyses of the VERITAC-2 Phase 3 trial, circulating tumor DNA (ctDNA) biomarker analyses from a Phase 1/2 study, real-world prevalence of ESR1 mutations in metastatic breast cancer patients, and results from the I-SPY2 Endocrine Optimization Pilot (EOP).
Key presentation details are:
Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
- Presenting Author: Erika P. Hamilton
- Presentation Number: PD10-03
- Presentation Type: Poster Spotlight Presentation
- Session: Poster Spotlight 10: Novel Combinations with Endocrine Therapy
- Date: Friday, December 12, 2025
- Session Time: 7:00–8:30 AM CT
- Presentation Time: 7:36–7:39 AM CT
Circulating tumor DNA (ctDNA) biomarker analyses of a phase 1/2 study evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
- Presenting Author: Seth A. Wander
- Presentation Number: PS2-07-24
- Presentation Type: Poster Presentation
- Session: Poster Session 2
- Date: Wednesday, December 10, 2025
- Session Time: 5:00–6:30 PM CT
Real-world prevalence of ESR1 mutations (ESR1m) among patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) after first-line (1L) treatment with endocrine therapy (ET) and/or a cyclin dependent kinase 4/6 inhibitor (CDK4/6i)
- Presenting Author: David Chandiwana
- Presentation Number: PS1-11-09
- Presentation Type: Poster Presentation
- Session: Poster Session 1
- Date: Wednesday, December 10, 2025
- Session Time: 12:30–2:00 PM CT
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)
- Presenting Author: Jo Chien
- Presentation Number: PD10-02
- Presentation Type: Poster Spotlight Presentation
- Session: Poster Spotlight 10: Novel Combinations with Endocrine Therapy
- Date: Friday, December 12, 2025
- Session Time: 7:00–8:30 AM CT
- Presentation Time: 7:33–7:36 AM CT
The I-SPY2 EOP trial is sponsored by Quantum Leap.
A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER+/HER2− locally advanced or metastatic breast cancer
- Presenting Author: Fengting Yan
- Presentation Number: PS5-09-30
- Presentation Type: Poster Presentation (Trial in Progress Poster)
- Session: Poster Session 5
- Date: Friday, December 12, 2025
- Session Time: 12:30–2:00 PM CT
Arvinas reported that the U.S. Food and Drug Administration (FDA) is reviewing the New Drug Application (NDA) for vepdegestrant, with a Prescription Drug User Fee Act (PDUFA) action date set for June 5, 2026. The FDA has granted Fast Track designation to vepdegestrant.
Arvinas is a clinical-stage biotechnology company focusing on protein degradation therapies. Its lead investigational drugs include ARV-102, ARV-393, ARV-806, and vepdegestrant.
Jeff Boyle, Investor Contact:
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Kirsten Owens, Media Contact:
+1 (203) 584-0307
Kirsten.owens@arvinas.com
Source: Arvinas
